An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma

1. Rodríguez Otero, P.
2. Towle, K.
3. Cope, S.
4. Caisip, C.
5. Davies, F.E.
6. Delforge, M.
7. Weisel, K.
8. Marshall, T.S.
9. Karampampa, K.
10. Ayers, D.
11. Mojebi, A.
12. Braverman, J.
13. Farrell, J.
14. Dhanda, D.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1080/10428194.2023.2235042 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus